molecular immunology at The Pasteur Institute and earned an M.D. and Ph.D. from the University of Paris, and an M.B.A. from Columbia University. Jeani Delagardelle, (57), Managing Director, helped found New Leaf in 2005. She joined Sprout in 2000. At New Leaf, Jeani leads the Medical Device investment effort. Jeani is currently on the boards of directors of Access Closure, Altura, Cardiokinetix, Direct Flow Medical, Intrinsic Therapeutics, ReShape Medical, and Spiracur. She was previously on the boards of directors of Interlace (NLV-I company acquired by Hologic), Epicor (acquired by St. Jude), Visiogen (acquired by Abbott), PercuSurge (acquired by Medtronic), and NxStage Medical (NASDAQ: NXTM). Prior to joining the healthcare investment team at Sprout, Jeani was a General Partner at Weiss, Peck & Greer Venture Partners (“WPGVP”) where she focused on healthcare investments. Before joining the venture industry, Jeani spent 16 years in senior marketing and general management positions in both the medical device and pharmaceutical industries. She was Vice President of Global Marketing for Target Therapeutics, held several senior management positions within the Medi-tech division of Boston Scientific, and served as the Director of Business operations for Roche Pharmaceuticals. Jeani earned an A.B. in Clinical Psychology from Occidental College and an M.B.A. from the University of California at Irvine. Ron Hunt, (49), Managing Director, joined Sprout in 1998 and helped found New Leaf in 2005. He has played significant role in the firm’s investment activities in later stage biopharmaceuticals and has also contributed to the activities in each of the other sectors. Ron is currently on the boards of Durata Therapeutics (NASDAQ: DRTX), IlluminOss Medical, Relypsa (NASDAQ: RLYP), and SpineWave. Ron was previously on the boards of Cerexa (NLV-I company acquired by Forest Laboratories), Stromedix, Inc. (NLV-I company acquired by Biogen Idec), Aspreva Pharmaceuticals (NASDAQ: AS